MallInckrodt Plc (MNK) - Financial and Strategic SWOT Analysis Review

  • ID: 4278971
  • SWOT Analysis
  • 56 pages
  • GlobalData
  • Mallinckrodt Pharmaceuticals Plc.
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Co
  • Johnson Matthey Plc
  • Merck & Co Inc
  • Mylan NV
  • Synthomer plc
  • MORE
MallInckrodt Plc (MNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Mallinckrodt Plc (Mallinckrodt) is develops, produces, commercializes, and distributes specialty pharmaceutical therapies and products. The company offers both branded and specialty generics for autoimmune and rare diseases in the specialty therapeutic areas of rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers analgesics and gastrointestinal products and immunotherapy and neonatal respiratory critical care therapies; active pharmaceutical ingredients (APIs) and external manufacturing services. The company sells its products either directly or through distributors to retail pharmacies, institutions and various end users. It has subsidiaries in Prince Edward Island, Ireland, Bermuda, Germany, Australia, Canada, Maryland, Delaware, Massachusetts, the UK, California, Netherlands, Alberta, Switzerland, and Luxembourg. Mallinckrodt is headquartered in Surrey, the UK.

MallInckrodt Plc Key Recent Developments

Jun 22, 2018: Deception technology applied to pharma cybersecurity
Jun 21, 2018: Mallinckrodt Launches Scientific Advisory Council
May 08, 2018: Mallinckrodt Reports First Quarter 2018 Results
Apr 04, 2018: Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018
Apr 04, 2018: Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Eli Lilly and Co
  • Johnson Matthey Plc
  • Merck & Co Inc
  • Mylan NV
  • Synthomer plc
  • MORE
Section 1 - About the Company
  • MallInckrodt Plc - Key Facts
  • MallInckrodt Plc - Key Employees
  • MallInckrodt Plc - Key Employee Biographies
  • MallInckrodt Plc - Major Products and Services
  • MallInckrodt Plc - History
  • MallInckrodt Plc - Company Statement
  • MallInckrodt Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • MallInckrodt Plc - Business Description
  • Business Segment: Other
  • Performance
  • Business Segment: Specialty Brands
  • Overview
  • Performance
  • Business Segment: Specialty Generics
  • Overview
  • Performance
  • Geographical Segment: Europe, Middle East and Africa
  • Performance
  • Geographical Segment: Other
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • MallInckrodt Plc - Corporate Strategy
  • MallInckrodt Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • MallInckrodt Plc - Strengths
  • MallInckrodt Plc - Weaknesses
  • MallInckrodt Plc - Opportunities
  • MallInckrodt Plc - Threats
  • MallInckrodt Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • MallInckrodt Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Jun 21, 2018: Mallinckrodt Launches Scientific Advisory Council
  • May 08, 2018: Mallinckrodt Reports First Quarter 2018 Results
  • Apr 04, 2018: Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018
  • Apr 04, 2018: Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors
  • Feb 27, 2018: Mallinckrodt Reports Fourth Quarter and Fiscal 2017 Results, Announces 2018 Guidance and Sets 2018 Strategic Priorities
  • Feb 21, 2018: Mallinckrodt Earns Somerset County Planning Board Land Development Honor
  • Feb 21, 2018: Mallinckrodt Earns Somerset County Planning Board Land Development Honor
  • Nov 07, 2017: Mallinckrodt Reports Earnings Results for Third Quarter of Fiscal 2017
  • Oct 23, 2017: Mallinckrodt Presents Health Economic Data Related to Hepatorenal Syndrome at The Liver Meeting 2017, the Annual Meeting of the American Association for the Study of Liver Diseases
  • Oct 16, 2017: Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • MallInckrodt Plc, Key Facts
  • MallInckrodt Plc, Key Employees
  • MallInckrodt Plc, Key Employee Biographies
  • MallInckrodt Plc, Major Products and Services
  • MallInckrodt Plc, History
  • MallInckrodt Plc, Other Locations
  • MallInckrodt Plc, Subsidiaries
  • MallInckrodt Plc, Key Competitors
  • MallInckrodt Plc, Ratios based on current share price
  • MallInckrodt Plc, Annual Ratios
  • MallInckrodt Plc, Annual Ratios
  • MallInckrodt Plc, Annual Ratios
  • MallInckrodt Plc, Interim Ratios
  • MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • MallInckrodt Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • MallInckrodt Plc, Performance Chart (2013 - 2017)
  • MallInckrodt Plc, Ratio Charts
  • MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Synthomer plc
  • Mylan NV
  • Merck & Co Inc
  • Johnson Matthey Plc
  • Eli Lilly and Co
  • Bayer AG
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll